Association of red blood cell distribution width and high sensitivity c-reactive protein with polycystic ovarian syndrome

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder characterized by chronic anovulation and hyperandrogenism. C-reactive protein is an acute-phase reactant protein released into the blood within a few hours after tissue injury and inflammation. It is usually a screening marker for intravascular inflammation.

Objective: To investigate the association between RDW-CV and high-sensitivity CRP (hsCRP) in PCOS.

Materials and methods: In this case-control study, 100 women (50 with PCOS and 50 without PCOS as the control group) were enrolled. We measured the high-sensitivity C-reactive protein (hsCRP) level and red blood cell (RBC) distribution width (RDW-CV) in women with PCOS compared with normal women.

Results: The mean age was 28.2 years for POCS and 29.9 years for healthy control. The mean (SD) body mass indexes were 27.5 (3.9) kg/m2 for PCOS and 27.7 (2.8) kg/m2 for healthy women. The significant result was found in mean (SD) LH level which was 4.8 (1.9) IU/L for POCS and 3.1 (1.2) IU/L for control group (p=0.001), while mean (SD) FSH levels were significantly high in normal group 6.9 (2.9) IU/L and lower in the PCOS women 5.5(1.2) IU/L. In addition, prolactin (p=0.3), Hb (p=0.7), E2 (p=0.6), and ET (p=0.6) levels were not significantly different between the two groups. RDW-CV levels were significantly higher in the PCOS women compared with the control individuals (13.4% vs. 11.9%), in addition, hsCRP levels were significantly higher in the PCOS women (1.9 mg/L vs. 0.9 mg/L) (p<0.0001).

Conclusion: As a result, there is a significant increase in the levels of hsCRP and RDW-CV in women with PCOS, which may be indicators of cardiovascular disease risk in the future.

Full Text

Restricted Access

About the authors

Basima Shamkhi Al-Ghazali

Kufa University

Email: ayam.mohammad@yahoo.com
ORCID iD: 0000-0002-5149-2848

Department of Gynecology, College of Medicine

Iraq, Kufa

Marwa Faisal Salman

Al-Najaf Health Directorate, Ministry of Health

Email: ayam.mohammad@yahoo.com

Department of Gynecology

Iraq, Al-Najaf

Ahmed Muhi Fahad

Al-Najaf Health Directorate, Ministry of Health

Author for correspondence.
Email: ayam.mohammad@yahoo.com
ORCID iD: 0000-0003-3748-681X

Department of Cardiothoracic and Vascular Surgery, Al-Sadder Teaching Medical City

Iraq, Al-Najaf

References

  1. Schrage J., Schaffer J. Polycystic ovarian syndrome and hyperandrogenism. In: Williams gynecology. 2nd ed. China: McGraw–Hill companies; 2008: 383-401.
  2. Bargiota A., Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther. Adv. Endocrinol. Metab. 2012; 3(1): 27-47. https://dx.doi.org/10.1177/2042018812437355.
  3. Tomlinson J.A., Pinkney J.H., Evans P., Millward A., Stenhouse E. Screening for diabetes and cardio-metabolic disease in women with polycystic ovary syndrome. The British Journal of Diabetes & Vascular Disease. 2013; 13(3): 115-23. https://dx.doi.org/10.1177%2F1474651413495571.
  4. Goldenberg N., Glueck C. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol. 2008; 60(1): 63-75.
  5. Carmina E., Bucchieri S., Esposito A., Del Puente A., Mansueto P., Orio F. et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J. Clin. Endocrinol. Metab. 2007; 92(7): 2500-5. https://dx.doi.org/10.1210/jc.2006-2725.
  6. Makedos A., Goulis D.G., Arvanitidou M., Mintziori G., Papanikolaou A., Makedou A., Panidis D. Increased serum C-reactive protein levels in normal weight women with polycystic ovary syndrome. Hippokratia. 2011; 15(4): 323-6.
  7. Park R., Detrano R., Xiang M., Fu P., Ibrahim Y., LaBree L., Azen S. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation. 2002; 106(16): 2073-7. https://dx.doi.org/10.1161/01.cir.0000033819.29662.09.
  8. Lagrand W.K., Visser C.A., Hermens W.T., Niessen H.W., Verheugt F.W., Wolbink G.J., Hack C.E. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999; 100(1): 96-102. https://dx.doi.org/10.1161/01.cir.100.1.96.
  9. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102(18): 2165-8. https://dx.doi.org/10.1161/01.cir.102.18.2165.
  10. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103(15): 1933-5. https://dx.doi.org/10.1161/01.cir.103.15.1933.
  11. Tonelli M., Sacks F., Arnold M., Moye L., Davis B., Pfeffer M.; for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation. 2008; 117(2): 163-8. https://dx.doi.org/10.1161/CIRCULATIONAHA.107.727545.
  12. Kolodgie F.D., Gold H.K., Burke A.P., Fowler D.R., Kruth H.S., Weber D.K. et al. Intraplaque hemorrhage and progression of coronary atheroma. N. Engl. J. Med. 2003; 349(24): 2316-25. https://dx.doi.org/10.1056/NEJMoa035655.
  13. Arbustini E., Morbini P., D'Armini A.M., Repetto A., Minzioni G., Piovella F. et al. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation. Heart. 2002; 88(2): 177-82. https://dx.doi.org/10.1136/heart.88.2.177.
  14. Tillett W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 1930; 52(4): 561-71. https://dx.doi.org/10.1084/jem.52.4.561.
  15. Trichopoulos D., Psaltopoulou T., Orfanos P., Trichopoulou A., Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomarkers Prev. 2006; 15(2): 381-4. https://dx.doi.org/10.1158/1055-9965.EPI-05-0626.
  16. Boulman N., Levy Y., Leiba R., Shachar S., Linn R., Zinder O., Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J. Clin. Endocrinol. Metab. 2004; 89(5): 2160-5. https://dx.doi.org/10.1210/jc.2003-031096.
  17. Verit F.F. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch. Gynecol. Obstet. 2010; 281(6): 1009-14. https://dx.doi.org/10.1007/s00404-009-1226-6.
  18. Ramanand S.J., Ramanand J.B., Raparti G.T., Ghanghas R.R., Halasawadekar N.R., Patil P.T. et al. High sensitivity C-reactive protein (hs-CRP) and clinical characteristics, endocrine, metabolic profile in Indian women with PCOS: a correlation. Int. J. Reprod. Contracept. Obstet. Gynecol. 2014; 3(1): 118-26.
  19. Escobar-Morreale H.F., Luque-Ramírez M., González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertil. Steril. 2011; 95(3): 1048-58.e1-2. https://dx.doi.org/10.1016/ j.fertnstert.2010.11.036.
  20. Javedani M., Sheibani H., Madadi Y., Yoonesi L. Relationship between c-reactive protein and carotid artery intima media thickens in polycystic ovarian syndrome patients. Acta Medica Mediterranea. 2015; 31(7): 1393-8. Available at: http://eprints.iums.ac.ir/id/eprint/5245
  21. Oh J.Y., Lee J.A., Lee H., Oh J.Y., Sung Y.A., Chung H. Serum C-reactive protein levels in normal-weight polycystic ovary syndrome. Korean J. Intern. Med. 2009; 24(4): 350-5. https://dx.doi.org/10.3904/kjim.2009.24.4.350.
  22. Iuhas C., Costin N., Mihu D. High-sensitivity C-reactive protein in patients with polycystic ovary syndrome. Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 2012; 19(4): 389-96. Available at: https://rjdnmd.org/index.php/RJDNMD/article/view/256
  23. Perlstein T.S., Weuve J., Pfeffer M.A., Beckman J.A. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch. Intern. Med. 2009; 169(6): 588-94. https://dx.doi.org/10.1001/archinternmed.2009.55.
  24. Patel K.V., Ferrucci L., Ershler W.B., Longo D.L., Guralnik J.M. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch. Intern. Med. 2009; 169(5): 515-23. https://dx.doi.org/10.1001/archinternmed.2009.11.
  25. Yilmaz Ö., Mehmet C., Kelekci S., Temur M. Association between red blood cell distribution width and polycystic ovary syndrome. Endocr. Res. 2015; 40(4): 181-7. https://dx.doi.org/10.3109/07435800.2014.987398.
  26. Zalawadiya S.K., Veeranna V., Niraj A., Pradhan J., Afonso L. Red cell distribution width and risk of coronary heart disease events. Am. J. Cardiol. 2010; 106(7): 988-93. https://dx.doi.org/10.1016/j.amjcard.2010.06.006.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies